EL7.AI
StocksMedium•30 July 2026•
1 min read

Hims & Hers Faces FTC Lawsuit While Accelerating International Growth via Acquisition

Key Facts

1Hims & Hers Health is facing an FTC lawsuit, though the company denies any wrongdoing.
2The acquisition of Eucalyptus is expected to add $200M+ in revenues in the second half of 2026.

Amid intensifying regulatory scrutiny of the digital healthcare sector, Hims & Hers Health is facing a lawsuit from the Federal Trade Commission (FTC) regarding alleged consumer protection violations. According to reports, the company has denied any wrongdoing and maintains its compliance with legal standards. This development comes at a critical juncture as the firm attempts to balance regulatory headwinds with its ambitious growth trajectory.

Despite these legal challenges, the company is accelerating its international expansion to offset regulatory concerns, with the acquisition of Eucalyptus expected to contribute over $200 million in revenue during the second half of 2026. This strategic move is designed to bolster financial forecasts for 2026 and 2027, providing a fundamental counterweight to the ongoing legal proceedings initiated by the FTC.

Operationally, the outlook remains mixed as markets monitor the progression of the legal dispute with U.S. authorities.